Gilead Completes Tender Offer for Myogen
14th Nov 2006, 16:19 GMT
Biotech company Gilead Sciences said it completed its cash tender offer for shares of Myogen Gilead said preliminary results show about 40.1 mln shares, or more than 91.3% of outstanding stock, were validly tendered and not withdrawn prior to the expiration of the tender offer.
Gilead Completes Tender Offer for Myogen related news:
- Gilead completes tender offer for Myogen — Pharmaceutical Business Review Latest News
- Gilead Sciences Successfully Completes Tender Offer for Shares of Myogen With Over 91.3% of Shares Tendered — Operations-Related News from StratCenter.com
- Gilead Sciences schließt Übernahmeangebot für Aktien von Myogen mit über 91,3 Prozent gehandelten Aktien erfolgreich ab — Nachrichten Ticker - www.finanzen.net
- Abbott Begins Kos Tender Offer — Financial News News from StratCenter.com
- Abbott Labs Commences Tender Offer for All Outstanding Shares of Kos Pharmaceuticals — StratWire - Business of Healthcare NewsFeed
- Gilead Sciences hält am Freitag, den 17. November, eine Präsentation auf der Credit Suisse Healthcare Conference — Nachrichten Ticker - www.finanzen.net
- Life Sciences 25 — Boston Globe -- Business News
- RealNetworks Secures 99% of WiderThan Shares; Extends Subsequent Offering Period of Tender Offer — PR Newswire: All Releases
- Abbott Laboratories Commences Tender Offer for All Outstanding Shares of Kos Pharmaceuticals, Inc. — PR Newswire: All Releases
- RealNetworks extends tender offer for WiderThan shares — bizjournals.com High Tech:Networking headlines
Latest news from Operations-Related News from StratCenter.com:
- Senior Housing Properties Trust Announces Proposed Public Offering of 5 mln Common Shares
- King Not Loving Its Shareholders
- Sepracor says asthma drug data is favorable
- Sepracor Presents Data on Asthma Drug
- Dr Reddy's Registers to List Shares
- PolyMedica Corp CEO to Ring the NASDAQ Stock Market Opening Bell
- Biovail to Present at the CSFB 2006 Healthcare Conference
- Genelabs reports lower Q3 loss
- Solexa posts narrowed Q3 loss
- Abbott's Humira Positive in 2 Studies